Literature DB >> 35121978

Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma.

Rached Alkallas1,2, Mathieu Lajoie1, Dan Moldoveanu1,3, Karen Vo Hoang1, Philippe Lefrançois4, Marine Lingrand1, Mozhdeh Ahanfeshar-Adams1, Kevin Watters5, Alan Spatz5,6, Jonathan H Zippin7, Hamed S Najafabadi2,8, Ian R Watson9,10.   

Abstract

The high background tumor mutation burden in cutaneous melanoma limits the ability to identify significantly mutated genes (SMGs) that drive this cancer. To address this, we performed a mutation significance study of over 1,000 melanoma exomes, combined with a multi-omic analysis of 470 cases from The Cancer Genome Atlas. We discovered several SMGs with co-occurring loss-of-heterozygosity and loss-of-function mutations, including PBRM1, PLXNC1 and PRKAR1A, which encodes a protein kinase A holoenzyme subunit. Deconvolution of bulk tumor transcriptomes into cancer, immune and stromal components revealed a melanoma-intrinsic oxidative phosphorylation signature associated with protein kinase A pathway alterations. We also identified SMGs on the X chromosome, including the RNA helicase DDX3X, whose loss-of-function mutations were exclusively observed in males. Finally, we found that tumor mutation burden and immune infiltration contain complementary information on survival of patients with melanoma. In summary, our multi-omic analysis provides insights into melanoma etiology and supports contribution of specific mutations to the sex bias observed in this cancer.
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 35121978      PMCID: PMC8832745          DOI: 10.1038/s43018-020-0077-8

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  72 in total

1.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

2.  The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

Authors:  Léon C L van Kempen; Margaret Redpath; Mounib Elchebly; Kathleen Oros Klein; Andreas I Papadakis; James S Wilmott; Richard A Scolyer; Per-Henrik Edqvist; Fredrik Pontén; Dirk Schadendorf; Anke F van Rijk; Stefan Michiels; Anne Dumay; Anne Helbling-Leclerc; Philippe Dessen; Jasper Wouters; Marguerite Stass; Celia M T Greenwood; Ghanem E Ghanem; Joost van den Oord; Jean Feunteun; Alan Spatz
Journal:  Sci Transl Med       Date:  2016-12-14       Impact factor: 17.956

Review 3.  [Functional heterogeneity of the limbic structures of the brain in organizing feeding and defensive behaviors].

Authors:  G M Chaĭchenko
Journal:  Usp Fiziol Nauk       Date:  1985 Jan-Mar

4.  Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials.

Authors:  Arjen Joosse; Sandra Collette; Stefan Suciu; Tamar Nijsten; Ferdy Lejeune; Ulrich R Kleeberg; Jan Willem W Coebergh; Alexander M M Eggermont; Esther de Vries
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

Review 5.  UV signature mutations.

Authors:  Douglas E Brash
Journal:  Photochem Photobiol       Date:  2014-11-28       Impact factor: 3.421

Review 6.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

7.  Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

Authors:  Arjen Joosse; Sandra Collette; Stefan Suciu; Tamar Nijsten; Poulam M Patel; Ulrich Keilholz; Alexander M M Eggermont; Jan Willem W Coebergh; Esther de Vries
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

8.  MuSiC: identifying mutational significance in cancer genomes.

Authors:  Nathan D Dees; Qunyuan Zhang; Cyriac Kandoth; Michael C Wendl; William Schierding; Daniel C Koboldt; Thomas B Mooney; Matthew B Callaway; David Dooling; Elaine R Mardis; Richard K Wilson; Li Ding
Journal:  Genome Res       Date:  2012-07-03       Impact factor: 9.043

9.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Authors:  Michael Krauthammer; Yong Kong; Byung Hak Ha; Perry Evans; Antonella Bacchiocchi; James P McCusker; Elaine Cheng; Matthew J Davis; Gerald Goh; Murim Choi; Stephan Ariyan; Deepak Narayan; Ken Dutton-Regester; Ana Capatana; Edna C Holman; Marcus Bosenberg; Mario Sznol; Harriet M Kluger; Douglas E Brash; David F Stern; Miguel A Materin; Roger S Lo; Shrikant Mane; Shuangge Ma; Kenneth K Kidd; Nicholas K Hayward; Richard P Lifton; Joseph Schlessinger; Titus J Boggon; Ruth Halaban
Journal:  Nat Genet       Date:  2012-07-29       Impact factor: 38.330

10.  OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations.

Authors:  Loris Mularoni; Radhakrishnan Sabarinathan; Jordi Deu-Pons; Abel Gonzalez-Perez; Núria López-Bigas
Journal:  Genome Biol       Date:  2016-06-16       Impact factor: 13.583

View more
  5 in total

1.  Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment.

Authors:  Eran Hodis; Elena Torlai Triglia; John Y H Kwon; Tommaso Biancalani; Labib R Zakka; Saurabh Parkar; Jan-Christian Hütter; Lorenzo Buffoni; Toni M Delorey; Devan Phillips; Danielle Dionne; Lan T Nguyen; Denis Schapiro; Zoltan Maliga; Connor A Jacobson; Ayal Hendel; Orit Rozenblatt-Rosen; Martin C Mihm; Levi A Garraway; Aviv Regev
Journal:  Science       Date:  2022-04-29       Impact factor: 63.714

Review 2.  Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.

Authors:  Aigli Korfiati; Katerina Grafanaki; George C Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; George Sakellaropoulos; Constantinos Stathopoulos
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

3.  Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma.

Authors:  Saul Carcamo; Christie B Nguyen; Elena Grossi; Dan Filipescu; Aktan Alpsoy; Alisha Dhiman; Dan Sun; Sonali Narang; Jochen Imig; Tiphaine C Martin; Ramon Parsons; Iannis Aifantis; Aristotelis Tsirigos; Julio A Aguirre-Ghiso; Emily C Dykhuizen; Dan Hasson; Emily Bernstein
Journal:  Cell Rep       Date:  2022-04-05       Impact factor: 9.995

Review 4.  DEAD-Box RNA Helicases DDX3X and DDX5 as Oncogenes or Oncosuppressors: A Network Perspective.

Authors:  Massimiliano Secchi; Camilla Lodola; Anna Garbelli; Silvia Bione; Giovanni Maga
Journal:  Cancers (Basel)       Date:  2022-08-06       Impact factor: 6.575

5.  Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes.

Authors:  Meng Wang; Ishani Banik; A Hunter Shain; Iwei Yeh; Boris C Bastian
Journal:  Genome Med       Date:  2022-06-16       Impact factor: 15.266

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.